Paolo Fava

List of Publications by Year in descending order

83 papers	1,880 citations	279778 23 h-index	289230 40 g-index
85 all docs	85 docs citations	85 times ranked	2809 citing authors

#	Article	IF	Citations
1	Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and SÃ©zary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. Journal of Clinical Oncology, 2015, 33, 3766-3773.	1.6	328
2	Targeting the ERK Signaling Pathway in Melanoma. International Journal of Molecular Sciences, 2019, 20, 1483.	4.1	116
3	Time course, clinical pathways, and longâ€term hazards risk trends of disease progression in patients with classic mycosis fungoides. Cancer, 2012, 118, 5830-5839.	4.1	105
4	Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Annals of Oncology, 2017, 28, 2517-2525.	1.2	98
5	Skin metastases of malignant melanoma: a clinical and prognostic survey. Melanoma Research, 2009, 19, 321-326.	1.2	61
6	Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study. Cancer Immunology, Immunotherapy, 2019, 68, 97-107.	4.2	61
7	Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab. European Journal of Cancer, 2015, 51, 2086-2094.	2.8	45
8	Blood Flow Cytometry in SÃ©zary Syndrome. American Journal of Clinical Pathology, 2015, 143, 57-69.	0.7	45
9	Radiotherapy and immune checkpoints inhibitors for advanced melanoma. Radiotherapy and Oncology, 2016, 120, 1-12.	0.6	44
10	Wide local excision vs. Mohs TÃ¼bingen technique in the treatment of dermatofibrosarcoma protuberans: a twoâ€centre retrospective study and literature review. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 2069-2076.	2.4	43
11	Isolation of extracellular vesicles improves the detection of mutant DNA from plasma of metastatic melanoma patients. Scientific Reports, 2020, 10, 15745.	3.3	41
12	Zosteriform Cutaneous Metastases. Dermatologic Surgery, 2009, 35, 1355-1363.	0.8	40
13	Melanoma of unknown primary site: a 33-year experience at the Turin Melanoma Centre. Melanoma Research, 2010, 20, 227-232.	1.2	39
14	Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution. Journal of Endocrinological Investigation, 2018, 41, 549-556.	3.3	39
15	Treatment of earlyâ€stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study*. British Journal of Dermatology, 2021, 184, 722-730.	1.5	39
16	Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management. Human Vaccines and Immunotherapeutics, 2016, 12, 1092-1101.	3.3	37
17	Complete regression of melanoma skin metastases after electrochemotherapy plus ipilimumab treatment: an unusual clinical presentation. European Journal of Dermatology, 2015, 25, 271-272.	0.6	36
18	Extracorporeal photopheresis for the treatment of erythrodermic cutaneous <scp>T</scp>â€cell lymphoma: a single center clinical experience with longâ€term followâ€up data and a brief overview of the literature. International Journal of Dermatology, 2013, 52, 1308-1318.	1.0	35

#	Article	IF	Citations
19	Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or SÃ©zary Syndrome. Journal of Investigative Dermatology, 2021, 141, 484-495.	0.7	31
20	Heterogeneity of Circulating CD4+ Memory T-Cell Subsets in Erythrodermic Patients: CD27 Analysis Can Help to Distinguish Cutaneous T-Cell Lymphomas from Inflammatory Erythroderma. Dermatology, 2008, 216, 213-221.	2.1	27
21	Spiky follicular mycosis fungoides: a clinicopathologic study of 8 cases. Journal of Cutaneous Pathology, 2015, 42, 164-172.	1.3	27
22	Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. Frontiers in Immunology, 2017, 8, 386.	4.8	27
23	<scp>HP</scp>yV6, <scp>HP</scp>yV7 and <scp>TSP</scp>yV <scp>DNA</scp> sequences detection in skin disease patients and healthy subjects. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 624-627.	2.4	25
24	Gauzeâ€based negative pressure wound therapy: a valid method to manage pyoderma gangrenosum. International Wound Journal, 2014, 11, 164-168.	2.9	23
25	CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab. European Journal of Cancer, 2018, 97, 59-61.	2.8	22
26	Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications. International Journal of Molecular Sciences, 2021, 22, 4561.	4.1	21
27	Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 575-582.	2.8	20
28	THERAPEUTIC HOTLINE: A rare vandetanib-induced photo-allergic drug eruption. Dermatologic Therapy, 2010, 23, 553-555.	1.7	19
29	Disease progression in melanoma patients with negative sentinel lymph node: does falseâ€negative specimens entirely account for this phenomenon?. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 242-248.	2.4	19
30	miRâ€155 expression in Primary Cutaneous Tâ€Cell Lymphomas (CTCL). Journal of the European Academy of Dermatology and Venereology, 2017, 31, e27-e29.	2.4	19
31	Long-Term Evolution of an Untreated Primary Cutaneous Follicle Center Lymphoma of the Scalp. American Journal of Dermatopathology, 2010, 32, 91-94.	0.6	18
32	Phenotypical characterization of circulating cell subsets in pyoderma gangrenosum patients: the experience of the Italian immunoâ€pathology group. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 655-658.	2.4	18
33	Human Endogenous Retrovirus Expression in Primary Cutaneous T-Cell Lymphomas. Dermatology, 2016, 232, 38-43.	2.1	18
34	The Microenvironmentâ€™s Role in Mycosis Fungoides and SÃ©zary Syndrome: From Progression to Therapeutic Implications. Cells, 2021, 10, 2780.	4.1	17
35	Metastatic melanoma treatment with checkpoint inhibitors in the COVIDâ€19 era: experience from an Italian Skin Cancer Unit. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1395-1396.	2.4	16
36	Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19. Seminars in Oncology, 2020, 47, 302-304.	2.2	15

#	Article	IF	Citations
37	High-dose immunoglobulines and extracorporeal photochemotherapy in the treatment of febrile ulceronecrotic Mucha-Habermann disease. Dermatologic Therapy, 2010, 23, 419-422.	1.7	13
38	Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives. Frontiers in Oncology, 2021, 11, 733770.	2.8	13
39	Cutaneous Melanoma Metastases Arising on a Split-Skin Graft Donor Site. Dermatologic Surgery, 2009, 35, 1282-1285.	0.8	12
40	Standardization of regimens in Narrowband UVB and PUVA in early stage mycosis fungoides: position paper from the Italian Task Force for Cutaneous Lymphomas. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 683-691.	2.4	12
41	Mycosis fungoides: disease evolution of the "lion queen" revisited. Giornale Italiano Di Dermatologia E Venereologia, 2012, 147, 523-31.	0.8	12
42	Melanoma Management during the COVID-19 Pandemic Emergency: A Literature Review and Single-Center Experience. Cancers, 2021, 13, 6071.	3.7	11
43	TCRÎ³-Chain Gene Rearrangement by GeneScan: Incidence and Significance of Clonal Heterogeneity in SÃ©zary Syndrome. Journal of Investigative Dermatology, 2010, 130, 2312-2319.	0.7	9
44	DNA from Human Polyomaviruses, MWPyV, HPyV6, HPyV7, HPyV9 and HPyV12 in Cutaneous T-cell Lymphomas. Anticancer Research, 2018, 38, 4111-4114.	1.1	9
45	Halo nevi related to treatment with imatinib in a dermatofibrosarcoma protuberans patient. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 244-245.	2.4	8
46	New Perspectives in the Pharmacological Treatment of Non-Melanoma Skin Cancer. Current Drug Targets, 2016, 17, 353-374.	2.1	8
47	Clinical Significance of Distant Metastasis-Free Survival (DMFS) in Melanoma: A Narrative Review from Adjuvant Clinical Trials. Journal of Clinical Medicine, 2021, 10, 5475.	2.4	8
48	Cutaneous B-cell lymphomas: Update on diagnosis, risk-stratification, and management. Presse Medicale, 2022, 51, 104109.	1.9	8
49	Differences in Clinicopathological Features and Distribution of Risk Factors in Italian Melanoma Patients. Dermatology, 2015, 230, 256-262.	2.1	6
50	Inflammatory Cutaneous Diseases in Renal Transplant Recipients. International Journal of Molecular Sciences, 2016, 17, 1362.	4.1	6
51	Identification of Risk Factors for Multiple Non-Melanoma Skin Cancers in Italian Kidney Transplant Recipients. Medicina (Lithuania), 2019, 55, 279.	2.0	6
52	Primary cutaneous B-cell lymphoma: narrative review of the literature. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 466-479.	0.8	6
53	Bexarotene as maintenance treatment after therapies other than skinâ€directed therapy in advancedâ€stage mycosis fungoides: a pilot study. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e367-e369.	2.4	5
54	Anti-BRAF/anti-MEK targeted therapies for metastatic melanoma patients during the COVID-19 outbreak: experience from an Italian skin cancer unit. Future Oncology, 2021, 17, 759-761.	2.4	5

#	Article	IF	Citations
55	Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy). Targeted Oncology, 2021, 16, 789-799.	3.6	5
56	Flow cytometric analyses of circulating regulatory T cells in patients with dermatitis herpetiformis and other immune mediated dermatoses. Giornale Italiano Di Dermatologia E Venereologia, 2013, 148, 197-201.	0.8	5
57	Intestinal involvement in toxic epidermal necrolysis. A case report and review of literature. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1843-1845.	2.4	4
58	Lack of detection of Cutavirus DNA using PCR real time in cutaneous T-cell lymphomas. Giornale Italiano Di Dermatologia E Venereologia, 2021, 155, 772-774.	0.8	4
59	Characterization and Management of Cutaneous Side Effects Related to the Immunosuppressive Treatment in Solid Organ Recipients. Current Drug Targets, 2017, 18, 436-446.	2.1	4
60	Treatment of metastatic melanoma: a multidisciplinary approach. Italian Journal of Dermatology and Venereology, 2017, 152, 241-261.	0.2	4
61	Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma. Journal of Clinical Medicine, 2021, 10, 4994.	2.4	4
62	Bullous pemphigoid in a renal transplant recipient. European Journal of Dermatology, 2014, 24, 383-384.	0.6	3
63	A study of melanoma in Eastern European migrants in Italy. European Journal of Dermatology, 2017, 27, 139-143.	0.6	3
64	Arrhythmias in a patient with metastatic melanoma treated with targeted therapy and implantable cardioverter defibrillator. British Journal of Dermatology, 2017, 177, 584-587.	1.5	3
65	Real-life use of phototherapy in early-stage mycosis fungoides from the Cutaneous Lymphoma Commission of the Italian Lymphoma Foundation: results of a web-based survey. Giornale Italiano Di Dermatologia E Venereologia, 2018, 153, 745-746.	0.8	3
66	Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study. Dermatologic Therapy, 2022, 35, e15492.	1.7	3
67	Time to next treatment and safety assessment in Cutaneousâ€Tâ€cell lymphomas: a retrospective analysis on patients treated with bexarotene and acitretin. British Journal of Dermatology, 0, , .	1.5	3
68	Cutaneous Metastases from Malignant Melanoma: Clinical Features and New Therapeutic Perspectives. , 2011, , .		2
69	HERV-E expression in peripheral mononuclear cells of patients with psoriasis. Italian Journal of Dermatology and Venereology, 2021, 156, .	0.2	2
70	Infections in SÃ©zary syndrome: A retrospective cohort study of 113 patients. Journal of the American Academy of Dermatology, 2021, , .	1.2	2
71	Evolution of different clinical patterns of cutaneous lesions in a suspected COVID-19 patient. European Journal of Dermatology, 2020, 30, 747-748.	0.6	2
72	CD38 Expression by Circulating and Skin-Infiltrating Lymphocytes from Sezary Syndrome Patients: A Flow Cytometry and Immunohistochemistry Study. Disease Markers, 2022, 2022, 1-7.	1.3	2

#	Article	IF	Citations
73	Molecular genetic analyses of human endogenous retroviral elements belonging to the <scp>HERV</scp>â€P and <scp>HERV</scp>â€R family in primary cutaneous Tâ€cell lymphomas. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e297-e298.	2.4	1
74	BRAFi/MEKi in patients with metastatic melanoma: predictive factors of complete response. Future Oncology, 2019, 15, 133-139.	2.4	1
75	Immunotherapy in transplanted patients: A special population that can no longer be ignored. Dermatologic Therapy, 2021, 34, e14975.	1.7	1
76	Melanoma Risk in Renal Transplanted Patients. Nephro-Urology Monthly, 2017, 9, .	0.1	1
77	A traveller's wart: tungiasis. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 236-237.	0.8	1
78	Guttate psoriasis in a patient with mycosis fungoides in treatment with Brentuximab vedotin: An unreported association. Dermatologic Therapy, 2022, , e15309.	1.7	1
79	SÃ©zary Syndrome: Different Erythroderma Morphological Features with Proposal for a Clinical Score System. Cells, 2022, 11, 333.	4.1	1
80	HERV-E expression in peripheral mononuclear cells of patients with psoriasis. Italian Journal of Dermatology and Venereology, 2021, 156, 42-45.	0.2	1
81	Extensive â€œhalo naeviâ€•phenomenon and regression of melanin during nivolumab treatment in metastatic melanoma: A predictor of a better outcome?. Dermatologic Therapy, 2022, 35, e15559.	1.7	1
82	Atopic dermatitis in a phenylketonuric untreated patient. International Journal of Dermatology, 2015, 54, 568-570.	1.0	0
83	Dermatological approach to vemurafenib skin toxicity: a single centre experience. Giornale Italiano Di Dermatologia E Venereologia, 2016, 151, 25-31.	0.8	0